R. Linke

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Yi‐Long Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology · 2017 · 1.2K citations

Oncology, Pathology, Bronchial Neoplasm +9

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and <i>EGFR</i>-Activating Mutations

Tony Mok, Ying Cheng, Xiangdong Zhou et al. · Journal of Clinical Oncology · 2018 · 428 citations

Compared Dacomitinib, Advanced Nsclc, Cancer Epidemiology +13

Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder

Ilonka Eisensehr, R. Linke, Soheyl Noachtar et al. · Brain · 2000 · 387 citations · Full text

Influence of cranioplasty on postural blood flow regulation, cerebrovascular reserve capacity, and cerebral glucose metabolism

Peter Winkler, Walter Stummer, R. Linke et al. · Journal of neurosurgery · 2000 · 337 citations

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial

Marine Gross‐Goupil, Tae‐Geon Kwon, Masatoshi Eto et al. · Annals of Oncology · 2018 · 252 citations · Full text